OA17131A - Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia - Google Patents
Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia Download PDFInfo
- Publication number
- OA17131A OA17131A OA1201400427 OA17131A OA 17131 A OA17131 A OA 17131A OA 1201400427 OA1201400427 OA 1201400427 OA 17131 A OA17131 A OA 17131A
- Authority
- OA
- OAPI
- Prior art keywords
- administered
- compound
- combination
- cytarabine
- route
- Prior art date
Links
- 206010000880 Acute myeloid leukaemia Diseases 0.000 title claims abstract description 49
- 201000006934 chronic myeloid leukemia Diseases 0.000 title claims abstract description 42
- 229960000684 Cytarabine Drugs 0.000 claims abstract description 54
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims abstract description 53
- UARVFMMJGJJSNR-UHFFFAOYSA-N 1-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea Chemical compound CC(C)(C)NC(=O)NC1=NC2=NC(NC3=CC4=NSN=C4C=C3)=NC=C2C=C1C1=C(Cl)C=CC=C1Cl UARVFMMJGJJSNR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 206010008943 Chronic leukaemia Diseases 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 135
- 238000001990 intravenous administration Methods 0.000 claims description 41
- 238000007912 intraperitoneal administration Methods 0.000 claims description 19
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical group CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 6
- 206010028549 Myeloid leukaemia Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000002559 cytogenic Effects 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 3
- 230000001684 chronic Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 67
- 239000000203 mixture Substances 0.000 description 63
- 210000004027 cells Anatomy 0.000 description 34
- 230000035492 administration Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 28
- 108060001251 CD34 Proteins 0.000 description 22
- 102100016492 CD34 Human genes 0.000 description 22
- 101700017647 CD33 Proteins 0.000 description 19
- 102100016493 CD33 Human genes 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 14
- -1 midaustorin Chemical compound 0.000 description 14
- 230000000259 anti-tumor Effects 0.000 description 13
- 230000002354 daily Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 206010024324 Leukaemias Diseases 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000002609 media Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drugs Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 210000004369 Blood Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 239000007759 RPMI Media 1640 Substances 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 210000001185 Bone Marrow Anatomy 0.000 description 3
- 101710009074 FLT3 Proteins 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 102000030951 Phosphotransferases Human genes 0.000 description 3
- 108091000081 Phosphotransferases Proteins 0.000 description 3
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 3
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002588 toxic Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 210000004881 tumor cells Anatomy 0.000 description 3
- 230000001173 tumoral Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 210000002960 BFU-E Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000003013 Erythroid Precursor Cells Anatomy 0.000 description 2
- 102100004573 FLT3 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 230000036882 MTD Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229940068917 Polyethylene Glycols Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229960004063 Propylene glycol Drugs 0.000 description 2
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical compound OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- HWKQNAWCHQMZHK-UHFFFAOYSA-N Trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000003868 ammonium compounds Chemical class 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory Effects 0.000 description 2
- 230000001028 anti-proliferant Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 230000003021 clonogenic Effects 0.000 description 2
- 239000003636 conditioned culture media Substances 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002449 erythroblastic Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000002709 granulomonocytic Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000644 propagated Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- JLEHSYHLHLHPAL-UHFFFAOYSA-N tert-butylurea Chemical compound CC(C)(C)NC(N)=O JLEHSYHLHLHPAL-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- KWMLJOLKUYYJFJ-AIECOIEWSA-N (2R,3R,4R,5S,6R)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-AIECOIEWSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N 6-Fluoro-2-(2'-Fluoro-1,1'-Biphenyl-4-Yl)-3-Methylquinoline-4-Carboxylic Acid Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 102100016549 ANPEP Human genes 0.000 description 1
- 101710028178 ANPEP Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229960004176 Aclarubicin Drugs 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- CIDNKDMVSINJCG-GKXONYSUSA-N Annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 1
- 229940046844 Aromatase inhibitors Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229950010231 Brequinar Drugs 0.000 description 1
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100005826 CD19 Human genes 0.000 description 1
- 101700087100 CD19 Proteins 0.000 description 1
- 210000002791 CFU-M Anatomy 0.000 description 1
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 1
- 229960005069 Calcium Drugs 0.000 description 1
- 229960003563 Calcium Carbonate Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N Cypionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N Ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N Exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- HDVBZDRIUHRXAV-UHFFFAOYSA-N GTI2040 Chemical compound O=C1N=C(N)C(C)=CN1C1OC(COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)C(OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 HDVBZDRIUHRXAV-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960002989 Glutamic Acid Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229960004931 Histamine Dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N Histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N Lestaurtinib Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 229950001845 Lestaurtinib Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 210000000066 Myeloid Cells Anatomy 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100013574 POU2F1 Human genes 0.000 description 1
- 101710006192 POU2F1 Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N Phenylpropanoic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 210000004214 Philadelphia Chromosome Anatomy 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 240000001016 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000000389 T-Cell Leukemia Diseases 0.000 description 1
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 1
- 229960001603 Tamoxifen Drugs 0.000 description 1
- 239000005463 Tandutinib Substances 0.000 description 1
- 229950009893 Tandutinib Drugs 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N Tetrahydro-2-furanmethanol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229950009158 Tipifarnib Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N Zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940045686 antimetabolites antineoplastic Purine analogs Drugs 0.000 description 1
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 1
- 239000003976 antineoplastic alkaloid Substances 0.000 description 1
- 229940045719 antineoplastic alkylating agents Nitrosoureas Drugs 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 229940045688 antineoplastic antimetabolites Pyrimidine analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001411 chlormethine Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical group CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-M ethyl carbonate Chemical compound CCOC([O-])=O CQDGTJPVBWZJAZ-UHFFFAOYSA-M 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229950009429 exatecan Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003278 mimic Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 101700050775 oct-1 Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000011129 pharmaceutical packaging material Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- CKNPWBAXEKSCRG-UHFFFAOYSA-J satraplatin Chemical compound CC(=O)O[Pt-2]([NH3+])(Cl)(Cl)(OC(C)=O)[NH2+]C1CCCCC1 CKNPWBAXEKSCRG-UHFFFAOYSA-J 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- SRBFZHDQGSBBOR-KKQCNMDGSA-N β-D-xylose Chemical compound O[C@@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KKQCNMDGSA-N 0.000 description 1
Abstract
The present invention relates to combinations of N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea and cytarabine and their use for treating AML or CML.
Description
NOVEL COMBINATIONS FOR TREATING ACUTE MYELOID LEUKAEMIA OR CHRONIC MYELOID LEUKAEMIA
This invention relates to the treatment of leukaemias, in particular myeloid leukaemias.
Leukaemia is a cancerous disease of the bone marrow and the blood. Four types of leukaemia can be distinguished: chronic myeloid leukaemia, acute myeloid leukaemia, chronic lymphoid leukaemia and acute lymphoid leukaemia.
Myeloid leukaemias of the acute type with a rapid progression are called AML or acute myeloid leukaemia. Myeloid leukaemias of the chronic type with a graduai, less aggressive progression are called CML or chronic myeloid leukaemia. These are clonal diseases of the bone marrow characterized by a clonal expansion of myeloid cells which cannot differentiate normally and accumulate in the bone marrow and the blood.
According to a study by the American Cancer Society, it is estimated that 11,930 new cases of AML and 4,500 new cases of CML will be diagnosed in 2006 in the United States. Over the period from 2002 to 2006, the 5 year survival rate is 20.4% for AML and 42.3% for CML (Cancer Facts and Figures 2006, American Cancer Society, www.leukemia-lymphoma.org/).
According to the French-American-British (FAB) classification of 1976, there are 8 subtypes of AML, referred to as MO to M7, depending on the type of cells from which the leukaemia develops (Bennett et al, 1976, Proposais for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33 (4): 451-8).
About 95% of patients suffering from CML bear a gene translocation between chromosomes 9 and 22 of the leukaemic cells. This abnormality, known as Philadelphia chromosome (Ph1), causes prolifération and uncontrolled multiplication of ail the types of white cells and platelets.
Currently, severai drugs are available for the treatment of leukaemias. However, there remains a need for new active therapeutic compounds for the improvement of the strategies for treatment of patients suffering from leukaemia or the development of a treatment alternative to the treatments already known (Plo et al, Mol Pharmacol, 2002, 62:304-312).
The product N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N’-(1(1-dimethylethyl)-urea is described in the international application W02007/003765. Its formula Is shown below:
A process for préparation of the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino) -6-(2,6-dichlorophenyl)pyrido[2,3-dJpyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea is also described.
Although this compound can display a significant anti-tumour activity on cells in tests in vitro, new parameters such as the distribution of the compound in the tissues, the quantity of product in the sérum, the pharmacokinetics and the metabolism are involved in the in vivo effect obtained, not predictable on the basis of in vitro tests. It has moreover been demonstrated that in vitro antitumour activity is not always prédictive of in vivo activity (Cancer Res. 1988 Oct 1; 48(19): 5447-54, Cancer Chemother Pharmacol. 1996 38: 548-552).
W02008/102075 discloses in vivo anti-tumour activity of the compound N-[2(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-ylJ-N'(1,1-dimethylethyl)-urea in animais bearing human leukaemias.
Cyt ara bine is an anti métabolite drug, mainly used to treat acute leukaemias and non Hodgkin’s lymphoma (NHL).
The activity of a combination of the compound N-[2-(2,1,3-benzothiadiazol-5ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1.1 -dimethylethyl)-urea with cytarabine for treating AML or CML is however not disclosed in W02008/102075.
The présent invention concems the combination of the compound N-[2-(2,1,3benzothiadiazol-S-ylaminoJ-e-ÎZ.e-dichlorophenyOpyridop.S-dlpyrimidin-T-yll-N’-fl, 1dimethylethyl)-urea (A) with cytarabine (B).
Compound (A) as used herein refers to the compound N-[2-(2.1,3-benzothiadiazolS-ylaminoJ-e-^.e-dichlorophenylJpyridofZ.S-dJpyrimidin-T-yll-N'-fl.l-dimethylethyO-urea or a hydrate, a pharmaceutically acceptable sait or a solvaté thereof.
Compound (B) as used therein refers to cytarabine.
According to an object, the présent invention concems the use of said combination for treating acute myeloid leukaemia (AML).
According to an object, the présent invention concems the use of said combination for treating chronic myeloid leukaemia (CML).
According to an object, the combinations of the invention are synergistic.
The synergy is herein defined as an effect greater that the added effect of each ingrédient.
Said synergy is in particular achieved by the combinations of the invention In inhibiting AML or CML progression, or alleviating AML or CML, more particularly in inhibiting tumor volume and/or tumor weight Increase or in reducing tumor volume and/or tumor weight.
According to an embodiment, the compounds of formula (A) and (B) are in amounts that produce a synergistic effect.
The object of the présent invention relates to the uses cited above and below for the treatment of mammals, in particular human.
The combinations of the inventions are such that both active ingrédients may be administered sîmultaneously, separately or sequentially.
According to an embodiment, both active ingrédients may be administered according to the same administration route or by distinct administration route.
According to an embodiment, both active may be administered in the same dosage form or with separate dosage forms.
Cytarabine is generally administered by the intravenous route (iv) or by intraperitoneal route (ip).
N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d] pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea can be administered by the oral route, the intravenous route, the Intraperitoneal route, or by two or more routes such as by the intravenous route followed by an intraperitoneal route or by the intravenous route followed by an oral route, ln man, a conventional administration route is the intravenous route and/or the oral route. According to the invention, a particular administration route of (A) Is the intravenous route followed by the oral route.
In one embodiment, the combination of the Invention is for use for treating acute myeloid leukaemia wherein compound (A) is administered by the Intravenous route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination of the invention is for use for treating acute myeloid leukaemia wherein compound (A) is administered by the oral route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination of the invention is for use for treating acute myeloid leukaemia wherein compound (A) is administered by the intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination of the invention is for use for treating chronic myeloid leukaemia wherein compound (A) is administered by the intravenous route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination of the invention is for use for treating chronic myeloid leukaemia wherein compound (A) is administered by the oral route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination ofthe invention is for use for treating chronic myeloid leukaemia wherein compound (A) is administered by the intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.
In one embodiment, the combination ofthe invention is for use for treating chronic myeloid leukaemia wherein compound (A) is administered by the intraperitoneal route followed by the oral route and cytarabine (B) is administered by the intraperitoneal route.
According to an object, the présent invention provides for the combination for use for the treatment of AML or CML in patients résistant to standard chemotherapy.
According to another object, the présent invention provides for the combination for use for the treatment of AML or CML in high-risk cytogenetic patients.
The expression high-risk cytogenetic patients’ refer to AML or CML patients which display significantly lower rate of response, high-risk of relapse and/or poor survival.
In the présent invention, combination is administered according to a dosage scheme which enables the treatment of AML or CML The dosage scheme varies depending on the administration route and depending on the physical characteristics of the patient. The dosage schemes suitable for this purpose inciude those which display therapeutic efficacy for the treatment of AML or CML. The combination of the invention can be administered as often as is necessary to obtain the therapeutic effect sought.
The efficacy of the combination of the invention against AML or CML can be determined experimentally as in the following example which illustrâtes the invention.
The présent invention also relates to a kit comprising:
- At least one compound of formula (A),
- Cytarabine (B),
- Instructions for use in the treatment of AML or CML
The présent invention also provides for methods of treatment of AML or CML comprising administration of a combination of the invention to a patient in the need thereof.
The combinations of the invention may be administered in combination with one (or more) anti-cancer active principle(s), in particular antitumour compounds such as:
- alkylating agents such as the alkylsulphonates (busulfan), dacarbazine, procarbazine, cloretazine, the nitrogen mustards (chlormethine, melphalan, chlorambucil, cyclophosphamide, ifosfamide), the nitrosoureas such as carmustine, lomustine, semustine, streptozocine and altretamîne;
- antineoplastic alkaloids such as vincristine, Vinblastine, vinorelbine and vindesine;
- taxanes such as paclitaxel or taxotere;
- antineoplastic antibiotics such as actinomydn and bleomydn;
- intercalating agents such as mitoxantrone;
- antineoplastic antimetabolites: folate antagonists, methotrexate; inhibitors of purine synthesis; purine analogues such as mercaptopurine and 6-thioguanine; inhibrtors of pyrimidine synthesis, aromatase inhibitors, capecitabine, pyrimidine analogues such as fluorouracil, gemcitabine, cytarabine and cytosine arabinoside; brequinar and nelarabine;
- topoisomerase inhibitors such as irinotecan, exatecan, topotecan, teniposide, camptothedn or etoposide;
- anticancer hormone agonists and antagonists including tamoxifen;
- kinase inhibitors such as imatinib, nilotinib and dasatinib, midaustorin, sorafenib, lestaurtinib and tandutinib;
- growth factor inhibitors;
- antiinflammatories such as pentosan polysulphate, corticosteroids, prednisone and dexamethasone;
- ceplene (histamine dihydrochloride);
- anthracyclines such as daunorubidn, epirubidn, pirarubidn, idarubicin, zorubicin, aclarubicin, annamycin, doxorubicin, mrtomycin and methramycin;
- anticancer métal complexes, platinum complexes, cisplatin, carboplatin, oxaliplatin and satraplatin;
- alpha Interferon,
- triphenylthiophosphoramide;
- antiangiogenic agents;
- thalidomide;
- famesyl transferase inhibitors such as tipifarnib;
- DNA methyl transferase inhibitors such as MG98;
- immunotherapy adjuvants such as gemtuzumab ozogamicin and HuM 195;
- biotherapeutic agents such as CT388-IL3;
- antisense agents such as GTI-2040;
- vaccines.
The combinations of the invention may also be administered in combination with one or more other active principles useful in one of the pathologies mentioned above, for example an anti-emetic, analgésie, anti-inflammatory or anti-cachexia agent.
It is also possible to combine the compounds of the présent invention with a radiation treatment.
These treatments can be administered simultaneously, separately, sequentially. The treatment will be adapted by the doctor depending on the patient to be treated.
A pharmaceutically acceptable sait of the compound refers to a sait that is pharmaceutically acceptable and that retains pharmacological activity. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington’s Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, or S. M. Berge, et al., Pharmaceutical Salts, J. Pharm. Sci., 1977;66:1-19, both of which are incorporated herein by reference.
Examples of pharmaceutically acceptable add addition salts include those formed with inorganic acids such as hydrochioric acid, hydrobromic add, sulfuric add, nitric add, phosphoric add, as well as those salts formed with organic acids, such as acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, oxalic acid, maleic add, malonic add, sucdnic acid, fumaric acid, tartaric add, citric acid, benzoic acid, cinnamic acid, 3-(4-hydroxybenzoyl)benzolc acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic add, 4-chlorobenzenesulfonic add, 2naphthalenesulfonic add, 4-toluenesulfonic add, camphorsulfonic add, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-l-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic add, p-toluenesulfonic add, and salicylic add.
Simultaneous administration typically means that both compounds enter the patient at precisely the same time. However, simultaneous administration also includes the possibility that the compounds enter the patient at different times, but the différence in time is sufficiently miniscule that the first administered compound is not provided the time to take effed on the patient before entry of the second administered compound. Such delayed times typically correspond to less than 1 minute, and more typically, less than 30 seconds, ln one example, wherein the compounds are in solution, simultaneous administration can be achieved by administering a solution containing the combination of compounds. In another example, simultaneous administration of separate solutions, one of which contains the compound (A) and the other of which contains cytarabine (B) can be employed. ln one example wherein the compounds are in solid form, simultaneous administration can be achieved by administering a composition containing the combination of compounds.
ln other embodiments, the compounds are not simultaneously administered. ln this regard, the first administered compound is provided time to take effect on the patient before the second administered compound is administered. Generally, the différence in time does not extend beyond the time for the first administered compound to complété Its effect in the patient, or beyond the time the first administered compound is completely or substantiaily eliminated or deactivated in the patient. In one set of embodiments, the compound (A) is administered before cytarabine (B). In another set of embodiments, cytarabine (B) is administered before the compound (A). The time différence in nonsimultaneous administrations is typically greater than 1 minute, and can be, for example, precisely, at least, up to, or less than 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, two hours, three hours, six hours, nine hours, 12 hours, 24 hours, 36 hours, or 48 hours, or more than 48 hours.
In one set of embodiments, one or both of compounds are administered in a therapeutically effective (i.e., therapeutic) amount or dosage. A therapeutically effective amounf is an amount of the active ingrédient that, when administered to a patient by itself, effectively achieves at least partially the treatment of AML or CML (for example, inhibits tumor growth, stops tumor growth, or causes tumor régression). An amount that proves therapeutically effective amount in a given instance, for a particular subject, may not be effective for 100% of subjects sîmilarly treated for the disease or condition under considération, even though such dosage is deemed a therapeutically effective amount by skilled practitioners. The amount of the compound that corresponds to a therapeutically effective amount is strongly dépendent on the type and stage of AML/CML, the âge of the patient being treated, and other facts. In general, therapeutically effective amounts of these compounds are well-known in the art, such as provided in the supporting référencés cited above.
In another set of embodiments, one or both of the active ingrédients are administered in a sub-therapeutically effective amount or dosage. A sub-therapeutically effective amount is an amount that, when administered to a patient by itself, does not completely inhibit over time the biological activity of the intended target.
Whether administered in therapeutic or sub-therapeutic amounts, the combination of the invention should be effective in treating AML or CML. A sub-therapeutic amount of compound (A) can be an effective amount if, when combined with cytarabine (B), the combination ls effective in the treatment of AML or CML.
In some embodiments, the combination of compounds exhibits a synergîstic effect (i.e., greater than additive effect) in treating AML or CML, particularly in reducing a tumor volume and/or weight in the patient. In different embodiments, depending on the effective amounts used, the combination can either inhibit tumor growth and/or weight, achieve tumor stasis, or even achieve substantiai or complété tumor régression.
In some embodiments, as shown in the examples, Compound (A) can be administered at a dosage of about 5 mg/kg to 150 mg/kg daiiy in mice, in particular 10 to 50 mg/kg daily, more particularly 20 mg/kg. Cytarabine, meanwhile, can be administered in mice at a dosage of about 1 mg/kg to 250 mg/kg daily, more particularly about 31,5 mg/kg. Corresponding doses in human can be obtained accordingly. In particular, a typical dosage of cytarabine (B) in human is 2 to 6 mg/kg/day as a continuous IV infusion over 24 hours or in divided doses by rapid injection for 5 to 10 days. Compound (A) may be administered in human at doses composed between 0.01 mg/g and 1000 mg/kg daily, typically between 50-200 mg/m2. There may be spécial cases where higher or lower dosages are appropriate; such dosages do not fall outside the scope of the invention.
According to the normal practice, the dosage appropriate for each patient is determined by the doctor depending on the mode of administration, and the weight and/or response of the said patient.
The dosage regimen of each active ingrédient may be one, two, three or four administration a day or a continuous infusion over time.
As used herein, the term 'about* generally indicates a possible variation of no more than 10%, 5%, or 1% of a value. For example, “about 25 mg/kg will generally indicate, in its broadest sense, a value of 22.5-27.5 mg/kg, I.e., 25 ± 2.5 mg/kg.
While the amounts of active ingrédients should resuit in the effective treatment of AML or CML, the amounts, when combined, are preferably not excessively toxic to the patient (i.e., the amounts are preferably within toxicity limits as established by medical guidelines). In some embodiments, either to prevent excessive toxicity and/or provide a more efficacious treatment of AML or CML, a limitation on the total administered dosage is provided. Typically, the amounts considered herein for example are per day; however, half-day and two-day or three-day cycles also are considered herein.
Different dosage regimens may be used to treat AML or CML. In some embodiments, a daily dosage, such as any of the exemplary dosages described above, is administered once, twice, three times, or four times a day for at least three, four, five, six, seven, eight, nine, or ten days. Depending on the stage and severity of the leukaemia, a shorter treatment time (e.g., up to five days) may be employed along with a high dosage, or a longer treatment time (e.g., ten or more days, or weeks, or a month, or longer) may be employed along with a low dosage. In some embodiments, a once- or twice-daily dosage is administered every other day. In some embodiments, each dosage contains both the compound (A) and cytarabine (B), while in other embodiments, each dosage contains either the compound (A) or cytarabine (B). In yet other embodiments, some of the dosages contain both compound (A) and cytarabine (B), while other dosages contain only compound (A) or cytarabine (B).
The patient considered herein is typically a human. However, the patient can be any mammal for which AML or CML treatment is desired. Thus, the methods described herein can be applied to both human and veterinary applications.
The term treating or treatment, as used herein, indicates that the method has, at the least, mitigated abnormal cellular prolifération. For example, the method can reduce the rate of tumor growth in a patient, or prevent the continued growth of a tumor, or even reduce the size and/or weight of a tumor.
In another aspect, methods for preventing AML or CML in a patient are provided. In this regard, prévention dénotés causing the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet expérience or display symptoms of the disease. The methods comprise administering to the patient a combination as described herein. The methods comprise administering to the patient in need thereof a combination, as described herein.
Compounds (A) and (B), or their pharmaceutically acceptable salts or solvaté forms, In pure form or in an appropriate pharmaceutical composition, can be administered via any of the accepted modes of administration or agents known in the art. The compounds can be administered, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally. The dosage form can be, for example, a solid, semî-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, pills, soft elastic or hard gelatin capsules, powders, solutions, suspensions, suppositories, aérosols, or the like, preferably in unit dosage forms suitable for simple administration of précisé dosages. A particular route of administration is oral, particulariy one in which a convenient daily dosage regimen can be adjusted according to the degree of severity of the disease to be treated.
The active ingrédients or the combination thereof may be in the form of a solid (e.g.. a powder or tablet) or a liquid dosage form. The compositions may include optionally, one or more auxiliary (e.g., adjuvant) and/or one or more pharmaceutically acceptable carriers (i.e., vehicles or excipients) known in the art. The said excipients are selected depending on the desired pharmaceutical form and mode of administration, from the normal excipients which are known to the person skilled in the art. Auxiliary and adjuvant agents may include, for example, preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prévention of the action of microorganisms is generally provided by various antibacterial and antifungal agents, such as, parabens, chlorobutanol, phénol, sorbic acid, and the like. Isotonie agents, such as sugars, sodium chloride, and the like, may also be included. Prolonged absorption of an injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin. The auxiliary agents also can include wetting agents, emulsifying agents, pH buffering agents, and antioxidants, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylated hydroxytoluene, and the like.
Dosage forms suitable for parentéral injection may comprise physiologically acceptable stérile aqueous or non-aqueous solutions, dispersions, suspensions or émulsions, and stérile powders for reconstitution into stérile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, éthanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fiuidity can be maintained, for example, by the use of a coating such as lecrthin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
Solid dosage forms for oral administration include soft or hard capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicaicium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) bindera, as for example, cellulose dérivatives, starch, alignâtes, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retardera, as for example paraffin, (f) absorption acceleratora, as for example, quatemary ammonium compounds, (g) wetting agents, as for example, cety! alcohol, and glycerol monostearate, magnésium stéarate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stéarate, magnésium stéarate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents.
Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well-known in the art They can contain pactfying agents and can be of such composition that they reiease the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds also can be in mlcroencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
Liquid dosage forms for oral administration include pharmaceutically acceptable émulsions, solutions, suspensions, syrups, and élixirs. Such dosage forms are prepared, for example, by dissolving, disperaing, etc., an active ingrédient described herein, or a pharmaceutically acceptable sait thereof, and optional pharmaceuticai adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, éthanol and the like; solubilizing agents and emulsifiera, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,317131 butyleneglycol, dimethyl formamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.
Suspensions, In addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.
Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds described herein with, for example, suitable nonirrttating excipients or carriers such as cocoa butter, polyethyleneglycol or a supposrtory wax, which are solid at ordlnary températures but liquid at body température and therefore, melt while In a suitable body cavity and release the active component therein.
Dosage forms for topical administration may include, for example, ointments, powders, sprays, and Inhalants. The active component is admixed under stérile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as can be required. Ophthalmic formulations, eye ointments, powders, and solutions also can be employed.
Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of the compounds described herein, or a pharmaceutically acceptable sait thereof, and 99% to 1% by weight of a pharmaceutically acceptable excipient. In one example, the composition will be between about 5% and about 75% by weight of a compounds described herein, or a pharmaceutically acceptable sait thereof, with the rest being suitable pharmaceutical excipients.
Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art. Reference is made, for example, to Remington's Pharmaceutical Sciences, 18th Ed.. (Mack Pubiishing Company, Easton, Pa.. 1990).
A PEG400 22% / Solutol 5% / G5 73% formulation may be used for the administration by Intravenous route of compound (A).
A Labrasol 21% / Solutol 5% / HCl 0.001 N 74% formulation may be used for the administration by the oral route of compound (A).
Kits according to the invention Include package(s) comprising combinations of the invention. The phrase '‘package means any vessel containing compounds or compositions presented herein. In some embodiments, the package can be a box or wrapping. Packaging materials for use in packaging pharmaceutical products are wellknown to those of skill in the art. Examples of pharmaceutical packaging materials include, but are not limited to, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for a selected formulation and intended mode of administration and treatment.
The kit also can contain items that are not contained within the package but are attached to the outside of the package, for example, pipettes.
Kits can contain instructions for administering compounds or compositions of the invention to a patient. Kits also can comprise instructions for approved uses of compounds herein by regulatory agencies, such as the United States Food and Drug Administration. Kits also can contain labeling or product inserts for the inventive compounds. The package(s) and/or any product insert(s) may themselves be approved by regulatory agencies. The kits can include compounds in the solid phase or in a liquid phase (such as buffers provided) in a package. The kits also can include buffers for preparing solutions for conducting the methods, and pipettes for transfemng liquids from one container to another.
The term “tumor'' as used therein is understood to refer to solid and/or liquid tumors.
The detailed description and spécifie examples are given for illustration only since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. Further, the examples demonstrate the principle of the invention and cannot be expected to specifically illustrate the application of this invention to ail the examples where it will be obviously useful to those skilled In the prior art.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 Illustrâtes the évolution of the médian tumor weight (mg) following post tumor implantation in mice implanted with AML KG1 cells and treated with the combinations of the invention.
Figure 2 illustrâtes the évolution of the médian tumor weight (mg) following post tumor implantation in mice implanted with CML T1 cells and treated with the combinations of the invention.
Examples hâve been set forth below for the purpose of illustration and to describe certain spécifie embodiments of the invention. However, the scope of the claims is not to be in any way limited by the examples set forth herein.
EXAMPLES
EXAMPLE 1 : Activity on AML
Materials and methods
Cell lines and primary AML cells
Hematological malignant cell lines were obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig) and cultured in complété RPMI1640 medium containing 10% fêtai bovine sérum and antibiotics. Primary AML cells were obtained from patients seen at Toulouse Hospital (Toulouse, France) at the time of diagnosis and after written informed consent. Ail samples were evaluated for karyotypic abnormalities, immunologie phenotype, FLT3-acquired activating mutations (internai tandem duplications and kinase domain mutations), t (Mizuki M. et al., Blood 2000 96: 3907-3914; Fiebig H.H. et al., Eur. J. Cancer 2004, 40: 802-820) and inv (Bonnet D. et al„ Nat Med 1997 3: 730-737) mutations, and c-kit receptor-acquired mutations. Samples were stored in the Hémopathies Inserm Midi-Pyrénées (HIMIP) collection. Mononuclear cells were separated through a Fîcoll-Hypaque denstty gradient.
Reagents
For in vitro studies, compound (A) was dissoived at 10 mM in DMSO and diluted in complété RPMI-1640 medium or in phénol red-free complété RPMI-1640 medium in stérile 96-well polystyrène cell culture plates. For in vivo studies, compound (A) was prepared for intravenous (IV) or intraperitoneal (IP) administration by mixing 22% PEG400 with 5% solutol and 73% glucose in 5% water. For oral administration, compound (A), was prepared in a generally regarded as safe (GRAS) formulation composed of 21% labrasol with 5% solutol and 74% HCL 0.001 N. Solutions were kept on ice and administered as a bolus within 1 hour after formulation préparation. The volume of injection was 0.2 mL per mouse.
Myeloid leukemic ceil clonogenlc assay
The assay is as described by Récher and colleagues (Récher C. et al., Blood 2005; 105:2527-2534) with slight modifications. Briefly, cells were washed twice in PBS and suspended at 1 x 10s cell/mL in H4230 medium (Stem Cell Technologies) supplemented with 10% 5637-conditioned medium and appropriate dilutions of COMPOUND (A). Cells were then plated on 35 mm pétri dishes and incubated at 37’C in 5% CO2, fully humidified atmosphère. After 7 days, colonies (more than 20 cells) and clusters (more than 5 cells) were scored using an inverted microscope.
Clonogenlc assay with human tumor xenografts
Tumor xenografts were derived from patients* tumors engrafted subcutaneously in nude mice (Oncotest). Details of the clonogenic assay procedure hâve been described eariier (Fîebig H.H. et al., Eur. J. Cancer 2004,40:802-820).
Normal myeloid progenltor cell clonogenlc assay
Fresh CD34* human bone marrow cells were washed twice in Iscove modified Dulbecco medium (IMDM) containing 10% FCS and resuspended in H4230 medium supplemented with 10% 5637-conditioned medium for CFU-GM growth, in H4435 medium for CFU-M growth, and in H4535 medium for BFU-E growth. H4230, H4435, and H4535 medium were purchased from Stem Cell Technologies. The cells were then plated in 35mm Pétri dishes and incubated in a humidified CO2 incubator (5% CO2, 37’C) for 14 days. Colonies (>50 cells) were then scored under an inverted microscope.
Tumor Implantation studles ln SCID mlce
Eight-week-old female SCID mice were purchased from Charles River. The Committee of Animal Studies at Sanofi approved the protocol for animal expérimentation. This protocol and ail laboratory procedures comply with the French Législation, which implements the European Directives. Animais were received at least one week before the experiment to allow acclimatization. The animais were kept under a natural daylight cycle and given food and water ad libitum.
Ail tumor cell lines were obtained from DSMZ GmbH. Initially, cell fines were cultured in RPMI 1640 containing 10% FCS and antibiotics, and implanted subcutaneously in SCID mice (107 cells/mouse). When the tumor reached approximately
1000 mg, it was removed from the donor mouse, eut into fragments (2-3 mm diameter), placed in a phosphate buffer saline, and implanted bilaterally with a 12-gauge trocar.
Tumor fragments were propagated until stable growth behavior occurred (a stable doubling time), before using in experiments. Distribution was performed using body weight and tumor weight criteria with the Newlab oncology software (Newlab).
Changes from baseline in tumor volume were used to calculate the médian values in treated (ΔΤ) and control (AC) groups. AT/AC (%) is the ratio of médian at any chosen day (the last day before control mice are sacrificed owing to tumor size). AT/AC values can be translated to activity ratings: AT/AC <0: highly active, AT/AC <10%: very active, 10% <AT/AC <40%: active, AT/AC >40%: inactive. When AT/AC values are négative, the percentage of régression is evaluated. Partial régression (PR) is defined as a decrease > 50% of tumor volume at treatment initiation. Complété régression (CR) is defined as a decrease in tumor volume below the limit of palpation (T=10mm3). At study end, the number of tumor-free survivors (TFS), which correspond to mice without any détectable tumor, was determined. Both drug-related deaths and maximum percent relative mean net body weight loss were also determined. Médian times to reach tumor target size were compared using Log-Rank or Kruskal-Wallis multiple comparisons tests. A body weight loss nadir (mean of group) > 20% or 10% drug-related deaths were considered to indicate an excessive toxic dosage.
Results
Effect of COMPOUND (A) on normal and AML myeloid progenitors
The anti-proliferative activity of COMPOUND (A) was evaluated in 5 granulomonocytic and erythroblastic normal myeloid progenitors. The granulomonocytic progenitors (CFU-GM) were more résistant to COMPOUND (A) than leukemic progenitors with médian ICM: 788.1 nM, interquartile range: 463.5 nM, p = 0.0008, Mann Whitney test). In contrast, erythroblastic BFU-E progenitors were not significantly sensitive to COMPOUND (A) treatment than CFU-L cells with médian ICso: 218.8 nM (interquartile range: 225.3 nM, p = 0.3142, Mann Whitney test for unpaired data).
The anti-proliferative effect of COMPOUND (A) was also evaluated on the myeloid progenitors (CFU-L) of 29 AML patient samples using a clonogenic test (see Table 1 below). COMPOUND (A) potently inhibited colony formation in the majority of the tested samples, with ICso values ranging from 3.8 to >1000 nM. According to COMPOUND (A) activity ranges on normal hematopoietîc progenitors, leukemic samples were then classîfied as résistant or sensitive: résistant (N=4 samples, ICso minimum: 887.9 nM, maximum: >1000 nM), or sensitive (N = 26, ICso médian 171.7 nM, minimum: 3.8 nM, maximum: 531.6 nM) which represents 86.7% of the tested samples (see Table 1 below). In the high-risk cytogenetic group (i.e., patients 4, 11, 14, 19, 21, 23, 25, 27, 28 and 29), only 3 AML cell samples displayed résistance to treatment with COMPOUND (A) (patients 27. 28, 29). However, it was noteworthy that patient sample 11. harbouring a complex karyotype, was highly sensitive to treatment with COMPOUND (A).
Table 1: Evaluation of Compound (A) on the leukemia progenitors (CFU-L) of 30 AML patient samples using an ex vivo clonogenic test.
Patients number | Age | FAB | Immunologie phenotype | Karyotypic analysis | FLT3/c-kit | IC50 |
CFU-L (nM) | ||||||
1 | 73 | 2 | CD34-CD33- | 46XX | 0 | 3.8 |
2 | 76 | 2 | CD34+CD33+ | 47XX.+11 | f | 4.6 |
3 | 33 | 2 | CD34+CD33+ | 46XY+X,t(8;2I) | 1· | 18.6 |
4 | 19 | 5 | CD34+CD33+ | complex | 0 | 2631 |
5 | 37 | 2 | CD34+CD33+ | 46XX | t | 37.17 |
6 | 18 | 2 | CD34-CD33+ | 46XX | 1 | 52.6 |
7 | 81 | 2 | CD34+CD33+ | 46XY | t | 56.9 |
8 | 58 | 4 | CD34+CD33+ | 46XY | 0 | 79.49 |
9 | 69 | 2 | CD34+CD33+ | 46XY | 0 | 81.1 |
10 | 72 | t | CD34+CD33+ | 46XY, t(l;8) | t | 126.9 |
It | 38 | t | CD34+CD33+ | 46XY, t(9;ll) | 0 | 160.7 |
12 | 80 | 2 | CD34-CD33+ | 46XX | Not donc | 162.6 |
13 | 73 | t | CD34+CD33+ | 46XX | 0 | 167.9 |
14 | 70 | 1 | CD34+CD33+ | 46XY,del7q | 0 | 1753 |
15 | 42 | 2 | CD34+CD33- | 46XY | 0 | 213.1 |
16 | 40 | 5 | CD34-CD33+ | 46XY | 1 | 257.4 |
17 | 52 | t | CD34-CD33+ | 46XX | 1 | 295.2 |
18 | 78 | 5 | CD34+CD33+ | 47XY.+8 | O | 299.1 |
19 | 63 | 4 | CD34+CD33+ | 46XY,del7q-;lq | 0 | 302.9 |
20 | 15 | 2 | CD34+CD33+ | 46XY, t(8;2l) | 0* | 303.7 |
21 | 52 | 5 | CD34+CD33+ | 46XY, t(3;6) | 1 | 322J |
22 | 61 | 2 | CD34+CD33+ | 46XY | 1 | 3433 |
23 | 72 | t | CD34+CD33- | 46XX. 7q- | 0 | 407.6 |
24 | 38 | 2 | CD34+CD33+ | 46XX | 0 | 4533 |
25 | 80 | 2 | Not donc | 46XY | Not done | 531.6 |
26 | 47 | 4 | Not donc | 46XX | 1 | 887.9 |
27 | 9 | 5 | CD34-CD33+ | 46XX, t(l;ll) mil rear | Not done | >1000 |
28 | 55 | 1 | CD34+CD33+ | Complex | 0 | >1000 |
29 | 70 | 1 | CD34+CD33+ | Complex | 0 | >1000 |
Abréviations and annotations used: Age at D : âge at diagnosis; FAB : French 10 American British classification of leukemias; WBC : White Blood Count at diagnosis;
FLT3: FLT3 receptor mutation, i.e : 0: wild type receptor, 1: ITD : Internai Tandem Duplication mutation or D835 kinase domain mutation , or both mutations (ITD and kinase domain) hâve been screened in ail the tested samples; * détection of an activating mutation of c-kit receptor (D688).
In vivo effects of compound (A) In mice implanted with KG1 AML ceils
Mice bearing KG1a cells were treated with IV COMPOUND (A) 10 or 17 mg/kg daily from day 5 to day 13, and with IP COMPOUND (A) on days 15,16,18-20,22,24-26, 29 and 31. A 16.2% body weight loss was seen at nadir (day 22) with COMPOUND (A) 17 mg/kg, which was réversible after treatment was stopped. At 10 and 17 mg/kg, COMPOUND (A) was highly active: ΔΤ/AC evaluated on day 32 was négative at both dosages (-4.99 [range: -6.46, -3.66] and -4.70 [range: -6.90, -3.91], respectively). At both dosages, 10/10 animais experienced complété régression with 80% and 60% cures observed, respectively, on day 120 at these two dosages. Statistical analysis confirmed the activity of COMPOUND (A) at both dosages based on the tumor volume and on the time for tumors to reach 1000 mg.
Mice bearing KG1 cells were treated daily with IV COMPOUND (A) from day 19 to day 38 post-tumor inoculations at 10 and 25 mg/kg/day. At 25 mg/kg/day, the DT/DC was inferior to -14.27 (range: -29.81, -7.12). Body weight loss amounting to 18.2% was observed on day 29 at the end of the treatment period. Weight loss was réversible, indicating that 25mg/kg was the MTD. A total of 6 out of 6 animais experienced complété régressions (CR) and cures at MTD. At 10mg/kg/day, ΔΤ/âC was 17.45 (range: -0.52, 52.10), and one of six animais experienced CR. This indicated that COMPOUND (A) was active at 10 mg/kg, and highly active at 25 mg/kg. Statistical analysis confirmed the antitumor activity of COMPOUND (A) at these two dosages.
The anti-tumor activity of COMPOUND (A) was also evaluated in mice bearing KG1 cells when given by oral route. When two daily dosages of 40 mg/kg/day were given consecutively from day 15 to day 40, post-tumor inoculation, ΔΤ/AC was -3.80 (range: -5.21, -2.93). A maximum body weight loss of 14.4% was detected on day 28, which was rapidly réversible. None of the animais were cured but 7 animais out of 10 experienced a CR. When given orally once a day at 50 or 31.5 mg/kg, the DT/DC was 7.61 (range: 4.72, 12.88) or 19.72 (range: 15.81, 29.35) suggesting efficacy. However, at 19.8mg/kg, a ΔΤ/AC of 41.99 (range: 32.19,59.33) was observed, suggesting that there is no efficacy at this dose.
One aim was to generate an inhibitor of AML cells, which could be adminîstered by
IV and oral routes. The anti-tumor activity of COMPOUND (A) when dosed as a single agent, at a clinically relevant induction/consolidation regimen, was evaluated in very advanced KG1 bearing mice (1000 mg tumor size at the onset of treatment).
COMPOUND (A) was first adminîstered daily at 25 mg/kg IV from day 22 until day 30 post-tumor inoculation. Then the treatment was switched to daily oral dosing at 50 mg/kg or 2 x 40mg/kg as previously tested from day 31 to day 95. During the IV induction phase,
COMPOUND (A) dosed at 25 mg/kg was highly active and induced strong tumor régressions. At day 31, mice were treated daily with oral dosages of COMPOUND (A) at either 2 x 40 mg/kg or 1 x 50 mg/kg. While an immédiate re-growth of tumors was observed in the vehicle group, in mice treated with COMPOUND (A) at 1 x 50 mg/kg, tumors re-grew slowiy, and at the 2 x 40 mg/kg oral dosage, complété disappearance of tumors was noted. This experiment suggests that following an IV induction phase; COMPOUND (A) could be successfully given orally to mimic a consolidation phase in the clinic as a single agent.
Combination of cytarabine and compound (A) was evaluated in mice bearing KG1 cells (Figure 1).
Compound (A) 20 mg/kg was administered on days 16 to 20 by IV route and Cytarabine 31.5 mg/kg was administered by IP route on days 16 to 22.
Single agent cytarabine showed log cell kill-gross (LCK-g) of 1.6 with no CR, PR or cure. Compound (A) showed LCK-g of 2.4 with 83% CR and no cure. Combination of the two products elicited significant synergy: LCK-g of 5.9 with 100% CR and 66% cures (see figure 1). Combination of cytarabine and compound (A) also showed synergistic antitumor actîvity in mice implanted with Kasumi-1 and CML-T1 tumor cells.
EXAMPLE 2 : Actîvity on CML
The effect of Compound (A) injected IP with cytarabine on the development of the human chronic leukaemia CML-T1 implanted in mice was assessed as follows.
Materials and methods
Eight-week-old female SC1D mice were purchased from Charles River (L'arbresle, Lyon, France). All animais rested for 7 days prior to the onset of treatments, and animal protocole were approved by the Animal Studies Committee of Sanofi Aventis Recherche & Développement. This protocol and the laboratory procedures comply with French législation, which implements the European Directives. Animais were received at least one week before the experiment, to allow a perfect acclimatization. Animal health was examined at the day before tumor implantation and before randomization to ensure that only animais of good health were selected to enter in the testing procedures. They were housed in macroion type III cages with filter hoods in a stérile room in which the air is continuously filtered to avoid any contamination. The sterility of the room is checked once a month and the cages were sterilized at 121’C for 30 minutes before use and changed twice a week. Room température was maintained at 22’C, and relative humidity at 60110%. The animais were kept under a naturel daylight cycle. The animais were fed with RO3 irradiated at 10 kGy, purchased from UAR (91360 Epinay/Orge, France), and water sterilized at 121’C for 30 minutes. Water consumption was visually monitored daily and the bottles were changed twice a week. Food and water were given ad libitum. The animal bedding was produced by UAR and sterilized at 121’C for 30 minutes and renewed twice a week.
Compound (A) was prepared by mixing 5% DMSO with 10% Tween-80 and 85% H2O. Cytarabine (B) was prepared in water for injectable préparation (Aracytine®, also referred to as Ara-C).
Solutions were kept on ice and administered as a bolus within 1 hour after formulation. The volume of injection per mouse was 0.2 mL.
Animais were treated by intraperitoneal (IP) route on days 8, 9,11 to17 and 19 with COMPOUND (A) and on days 8,12 and 16 with Cytarabine.
Tumor Information and Implantation
CML-T1 is a human T cell leukemia established from the peripheral blood of a 36year-old woman with CML in blast crisis in 1987. Cells were described to express T cell surface markers and to hâve a Bcr-abl translocation (producing the p210 Bcr-abl protein) (Kuriyama et al Blood. 1989;74(4):1381-7). The immunology of the tumor is the following: CD2 -, smCD3 (+), cyCD3 +, CD4 +, CD5 +, CD6 +, CD7 +, CD8 +, CD13 -, CD19 -, CD34-, TCRalpha/beta -, TCRgamma/delta.
The techniques of chemotherapy and data analysis hâve been presented in details (Corbett et al., Invest. New Drugs 1998;16:129-39). Initially, this cell line was cultured in RPMI 1640 containing 10% foetal calf sérum (FCS) and antibiotics, and implanted subcutaneously in SCID mice (107 cells/mouse). When the tumor reached approxlmately 1000 mg, it was removed from the donor mice, cutted into fragments (2-3 mm diameter), placed in a phosphate buffer saline, and implanted bilaterally with a 12 gauge trocar. Tumor fragments were propagated until stable growth behavior occurred a stable doubling time (td), before using in experiments. Tumors fragments were frozen with 80% medium, 10% foetal calf sérum (FCS), 10% DMSO at 6-10 fragments/vial.
Grouping Identification and randomlzatlon of animais
The mice were within a 19-20 g weight range. Animais with a body weight inferior to 18 g were exduded of the study. On day 8, tumor bearing animais were stratified into severai groups. Only animais with 2 appropriate tumor volumes were selected and randomly distributed to treatment and control groups. The average tumor weight at start of therapy was 63-77 mg. Distribution was performed using body weight and tumor weight criteria with the Newlab oncology software (Newlab, 23 bd Europe, 54500 Vandoeuvre les Nancy, France). Each group consisted of 6-7 mice. At the beginning of the study, each cage was labelled with a record card, indicating the date of tumor implantation, tumor type, test compound and route of administration.
Criteria for assesslng antitumor activity
Chemotherapy was started on the day of grouping (8 days after tumor implantation). Mice were checked daily and adverse dinical reactions noted. Each parameter was measured and results recorded using the Newlab oncology* software.
Tumor Weights
Tu mors were measured with a caliper twice weekly until the tumor reached 2000 mg or until the animal died (which ever corne first). Tumor weights were estimated from 2 dimensional measurements: Weight (in mg) = (a x b2)#, where a and b* are the tumor length and width (mm) respectively. The total weight of the 2 implanted tumors is indicated.
Mice with complété régression (CR) consist in tumor régression below limit of palpation (<63 mg). At the end of the study, the number of tumor free survivors (TFS), which correspond to mice without tumor weight superiorto 63 mg, was determined.
Détermination of the tumor doubling time
The tumor doubling time (Td) is estimated in the control group, with the estimated slope a of the linear model of the log tumoral weight along day chosen in the exponential growth phase (100 to 1000 mg range), with Td = Iog2/a.
Quantification of tumor cell kill
For subcutaneous (SC) growing tumors, the total log cell kill-gross (LCK-g) is calculated from the following formula (Corbett et al., Invest. New Drugs 1998;16:129-39.):
The LCK-g = (T-C) value in days
3.32 xTd where T is the médian time (in days) required for the treatment group tumors to reach a predetermined size (eg, 1000 mg), and C is the médian time tumors to reach the same size (in days) for the vehicle group of each schedule. Tumor-free survivors are excluded from these calculations (cures are tabulated separately). T-C is the tumor growth delay and Td is the tumor doubling time in days. The conversion of the T-C values to LCK-g is possible because the Td of tumors regrowing post treatment approximates the Td values of the tumors in untreated control mice. LCK-g values can be translated into an activity rating, according to the Southem Research Institute (SRI) criteria:
SRI activity criteria | LCK gross (Treatment duration of 5-20 days) |
Highly active ++++ | >2.8 |
+++ | 2.0 to 2.8 |
++ | 1.3 to 1.9 |
+ Inactive | 0.7 to 1.2 |
- | <0.7 |
The second endpoint used to assess antitumor activity was the évaluation of the T/C. The T/C value in percent is an indication of antitumor effectiveness. The treatment and control groups are measured when the control group tumors reach approximately 700 to 1200 mg in size. A T/C equal to or less than 42% is considered significant antitumor activity by the Drug Evaluation Branch of the Division of Cancer Treatment of the National Cancer Institute.
Drug toxicity
A body weight loss nadir (mean of group) of greater than 20% or 10% drug deaths are considered to Indicate an excessively toxic dosage. Antitumor activity évaluation was done at the highest non toxic dose (HNTD).
Statistical analysis
In order to evaluate the compounds and association effects, a 3 way ANOVA with repeated measures on factor day was applied on log tumoral weight (until the maximum time measurement of vehicle group), followed by a Dunnetfs adjustment for multiplicity. Additional statistical analysis was done to evaluate synergism between the 2 products (COMPOUND (A) and Cytarabine) at fixed day, the association effect is compared to the sum of the effects of the compound alone at the defined doses. Ail Statistical analyses were performed on SAS V8.2 for Windows software.
A probability less than 5% (p<0.05) was considered as significant. The statistical analyses are included in an independent statistical report (TL06010-EN-E01).
RESULTS
The activity of COMPOUND (A) was determined in CML-T1 bearing mice. A control group (no treatment) and a vehicle-treated group are included in the study. These are made up of mice carrying tumors either untreated or treated with the vehide. The control group serves to study the effect of the vehide and the vehicle-treated group serves as reference to the different treatments.
Cytarablne treated groups :
Cytarabine was administered by IP route on days 8, 12 and 16 at 5 dosages (50, 100,150, 200, 250 mg/kg).
COMPOUND (A) treated groups:
COMPOUND (A) was administered by IP route on days 8, 9,11 to 17 and 19 at 4 dosages (10,17, 25 or 30 mg/kg/administration).
Cytarablne + COMPOUND (A) treated groups:
COMPOUND (A) and Cytarabine were administered by IP route respectively on days 8, 9,11 to 17 and 19 for COMPOUND (A) and on days 8,12 and 16 for Cytarabine.
Cytarabine 200 mg/kg (total dose = 600/100 mg/kg): a 4.4% body weight loss was observed on day 21 and no drug death was detected. LCK-g = 1.9 with 1 out of 7 animais considered as cured on day 141 at the end of the study. Compared to the different compounds at their respective doses, Cytarabine at 200 mg/kg produced only a 0.9 LCK-g and COMPOUND (A) at 10 mg/kg produced a 0.1 LCK-g. This indicated that this combination is active, producing a higher LCK-g than the isolated compounds at their respective doses. Statistical analyzes detected a synergistic effect on day 20 only of the experiment.
Results are illustrated on Figure 2.
CONCLUSION
Synergism has been evaluated on Iog tumoral weight at fixed day for a combination of dose of the 2 products by comparison of the sum of the effect of each product alone at these doses and the effect of this combination of the 2 products, compared with the vehicle Cytarabine + vehicle Compound (A) group. There is a sîgnificant synergism on day 20 between COMPOUND (A) at 10 mg/kg and Cytarabine at
200 mg/kg. The synergism becomes sîgnificant between ail Cytarabine doses and
COMPOUND (A) at 17 mg/kg on day 26.
Claims (20)
1. A combination comprising the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-
6-(2l6-dichlorophenyl)pyrido[2l3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a
5 hydrate, a sait or a solvaté thereof, with cytarabine (B) for use in the treatment of acute myeloid leukaemias.
2. A combination comprising the compound N-[2-(2,1,3-benzothîadiazol-5-ylamino)6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N’-(1,1-dimethylethyl)-urea (A) or a hydrate, a sait or a solvaté thereof, with cytarabine (B) for use in the treatment of chronic
10 myeloid leukaemias.
3. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intravenous route.
4. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the oral route.
15
5. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intravenous route followed by the oral route.
6. A combination for use according to claim 1 or 2, wherein compound (A) is administered by the intraperitoneal route.
7. A combination for use according to anyone of the preceding claims, wherein 20 cytarabine (B) is administered by the intravenous route.
8. A combination for use according to anyone of the preceding claims, wherein cytarabine (B) is administered by the intraperitoneal route
9. A combination for use according to claim 1, wherein compound (A) ls administered by the intravenous route and cytarabine (B) is administered by the
25 intravenous route.
10. A combination for use according to claim 1, wherein compound (A) ls administered by the oral route and cytarabine (B) is administered by the intravenous route.
11. A combination for use according to claim 1, wherein compound (A) is 30 administered by the Intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.
12. A combination for use according to claim 2, wherein compound (A) is administered by the intravenous route and cytarabine (B) is administered by the Intravenous route.
13. A combination for use according to claim 2, wherein compound (A) is administered by the oral route and cytarabine (B) is administered by the intravenous route.
14. A combination for use according to claim 2, wherein compound (A) is administered by the intravenous route followed by the oral route and cytarabine (B) is administered by the intravenous route.
15. A combination for use according to claim 2, wherein compound (A) is administered by the intraperitoneal route followed by the oral route and cytarabine (B) is administered by the intraperitoneal route.
16. A combination for use according to anyone of the previous daims wherein compounds (A) and (B) are administered simultaneously, separately or sequentially.
17. A combination for use according to anyone of the preceding daims, where it is for treating AML or CML patients résistant to standard chemotherapy.
18. A combination for use according to anyone of the preceding daims, where it is for treating AML or CML in high risk cytogenetic patients.
19. A kit comprising :
- the compound N-[2-(2,1,3-benzothiadiazo!-5-ylamino)-6-(2,6-dich!orophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N’-(1,1-dimethy!ethy!)-urea (A) or a hydrate, a sait or a solvaté thereof,
- cytarabine (B)
- instructions for use in the treatment of acute myeloid leukaemias.
20. A kit comprising :
- the compound N-[2-(2,1,3-benzothiadiazo!-5-ylamino)-6-(2,6-dich!orophenyl) pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-urea (A) or a hydrate, a sait or a solvaté thereof,
- cytarabine (B)
- instructions for use in the treatment of chronic myeloid leukaemias.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305295.3 | 2012-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17131A true OA17131A (en) | 2016-03-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL303038B1 (en) | Preservation of immune response during chemotherapy regimens | |
JP2020528880A (en) | Combination cancer therapy | |
AU2014251028A1 (en) | Ibrutinib combination therapy | |
CN111032043A (en) | Compositions and methods of use of 2- (4-chlorophenyl) -N- ((2- (2, 6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2, 2-difluoroacetamide | |
RU2739992C2 (en) | Apilimod compositions and methods of using them in treating colorectal cancer | |
US20160129003A1 (en) | Pharmaceutical Combinations | |
CA2872541A1 (en) | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease | |
KR20230113594A (en) | Combination therapy to treat PIK3CA mutant cancer | |
JP2014530181A (en) | Compositions and methods for treating cancer using PI3Kβ inhibitors and MAPK pathway inhibitors including MEK and RAF inhibitors | |
EP4218768A1 (en) | Combinations of imetelstat and venetoclax for use in the treatment of haematological cancer | |
RU2746705C2 (en) | Combination of bcl-2 inhibitor and mcl-1 inhibitor, use and pharmaceutical compositions thereof | |
US20150005253A1 (en) | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia | |
TW202134237A (en) | Treatment for acute myeloid leukemia or myelodysplastic syndrome | |
TWI433678B (en) | Novel therapeutic utilization for the treatment of leukaemias | |
JP6373252B2 (en) | Methods of treating cancer using aurora kinase inhibitors | |
OA17131A (en) | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia | |
Blumel et al. | Bendamustine: a novel cytotoxic agent for hematologic malignancies. | |
EP3200879A1 (en) | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii | |
JP2015515476A (en) | Method for treating cancer using PI3K inhibitor and MEK inhibitor | |
CN110121338A (en) | The combination of spleen tyrosine kinase inhibitor and other therapeutic agents | |
JP2023537290A (en) | Combinations of Bcl-2 inhibitors and hypomethylating agents, their uses and pharmaceutical compositions for treating cancer | |
NZ795224A (en) | Preservation of immune response during chemotherapy regimens | |
TW201315471A (en) | Compositions and methods for treating cancer using PI3K β inhibitor and mapk pathway inhibitor, including MEK and RAF inhibitors |